Cantharidin (Ycanth) — CPB 1051 | AETNA Coverage Update

Aetna modified CPB 1051 for cantharidin (Ycanth) coverage, effective January 5, 2026. Here's what billing teams need to know.

Aetna, a CVS Health company, updated its cantharidin coverage policy under CPB 1051 Aetna system to define medical necessity criteria for J7354 — the HCPCS code for cantharidin 0.7% single-dose applicator — used in treating molluscum contagiosum. The policy sets hard limits on session counts, applicator quantities, and lesion sites. If your dermatology or pediatric practice bills for Ycanth, this policy directly controls whether those claims pay or deny.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna
Policy	Cantharidin (Ycanth) — CPB 1051
Policy Code	CPB 1051
Change Type	Modified
Effective Date	January 5, 2026
Impact Level	Medium
Specialties Affected	Dermatology, Pediatrics, Family Medicine, Infectious Disease
Key Action	Confirm J7354 claims include B08.1, age verification (2+), and applicator count ≤ 2 per session before submitting

---

Aetna Cantharidin Coverage Criteria and Medical Necessity Requirements 2026

Aetna cantharidin coverage policy under CPB 1051 covers Ycanth for molluscum contagiosum — but only when five specific criteria are all met. Miss one, and you have a claim denial waiting to happen.

Here are the five criteria for initial approval:

Every single one of these must be satisfied. Aetna treats this as an "all criteria" gate, not a "most criteria" gate.

The applicator cap is the one most likely to generate a surprise denial. Two applicators per session is the ceiling. If a patient presents with extensive lesions and your provider uses a third applicator, document it carefully — or better yet, call your Aetna provider rep before the visit to understand how they handle medical exceptions.

On reimbursement, J7354 is listed as covered when selection criteria are met. Each applicator unit delivers 3.2 mg of cantharidin at 0.7% concentration. Bill J7354 per unit dose applicator used, up to two per session.

The policy does not explicitly require prior authorization in the printed criteria. That said, high-cost drug policies like this one frequently have prior auth requirements attached at the plan level even when the CPB itself doesn't state it. Check the member's specific plan benefits before the visit. If you're unsure, contact Aetna provider services and document the call.

---

Aetna Cantharidin Exclusions and Non-Covered Indications

Aetna is explicit here: all indications for Ycanth outside of molluscum contagiosum are experimental, investigational, or unproven. That language matters. Claims submitted with any diagnosis other than B08.1 will not meet medical necessity under this coverage policy.

Three site-specific exclusions also apply within the covered indication itself. Aetna will not cover Ycanth when applied to:

#	Excluded Procedure Copy
1	Oral lesions
2	Mucosal lesions
3	Ophthalmic lesions

This is clinically consistent with the FDA label, but it creates a documentation burden. Your chart notes and claim must support that the treated lesions were cutaneous — not any of the three excluded sites. If a patient has molluscum in or near these areas, Ycanth reimbursement is off the table under this policy.

---

Coverage Indications at a Glance

---

Aetna Cantharidin Billing Guidelines and Action Items 2026

The effective date for this modified policy is January 5, 2026. If your team has not updated workflows to match CPB 1051, do it now. Here's what needs to happen:

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Cantharidin Under CPB 1051

Covered HCPCS Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
J7354	HCPCS	Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg)

Other CPT Codes Related to CPB 1051

These codes are listed in relation to the policy. Review same-day billing rules before submitting with J7354.

Code	Type	Description Copy
17110	CPT	Destruction of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions
17111	CPT	Destruction of benign lesions other than skin tags or cutaneous vascular proliferative lesions; 15 or more lesions

Key ICD-10-CM Diagnosis Codes

Code	Description	Coverage Note Copy
B08.1	Molluscum contagiosum	Covered for cutaneous lesions only — not covered for oral, mucosal, or ophthalmic lesions

---

A Note on What This Policy Change Actually Means

This modification isn't a dramatic coverage expansion or restriction — it's a formalization of criteria that define the exact conditions under which Ycanth gets paid. The real issue here is operational. Aetna cantharidin billing has enough moving parts — applicator limits, session limits, site exclusions, training requirements — that errors are going to happen on autopilot.

The billing guidelines embedded in CPB 1051 are actually more detailed than what most payers publish for topical drug policies. That specificity is good for billing teams that read it. It's a claim denial factory for teams that don't.

Pediatric practices and dermatology groups with high molluscum volume should do a retrospective audit of any Ycanth claims submitted to Aetna before January 5, 2026. If you were billing three applicators per session or missing B08.1, you have exposure. Pull those claims and review them before Aetna does.

If your practice is new to Ycanth billing or your volume is growing, loop in your compliance officer or a billing consultant who handles dermatology payer policy. The applicator-per-session and session-per-infection limits create scenarios — like a patient with multiple sequential infections — where the rules aren't obvious without a closer read.

---